Valuation dashboard for Revvity, Inc. (RVTY) with P/E 78.94, P/B 2.56, EV/EBITDA 27.08 and dividend yield 0.17%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide.
Analysis Summary
Revvity, Inc. reported revenue of $2.86B in the most recent fiscal year, growing at a 5-year CAGR of -5.5%. Net income reached $241.7M, with a -19.8% 5-year CAGR.
Trailing-twelve-month margins: gross margin 52.1%, operating margin 12.3%, net margin 8.2%.
At $165.78 (closing price, October 29, 2026), RVTY trades at a P/E of 78.94 and an ROE of 3.27%. Market capitalisation stands at $18.5B, placing it among large-cap names.
Balance sheet quality for RVTY: current ratio of 1.7. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| P/E Ratio | 78.94 |
| Price / Book | 2.56 |
| EV / EBITDA | 27.08 |
| Dividend Yield | 0.17% |
Valuation Models
| DCF Fair Value | $110.68 |
| vs Current Price | -33.2% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RVTY | Revvity, Inc. | $18.5B | 78.94 | 2.56 | 3.3% |
| TECH | Bio-Techne Corporation | $11.4B | 62.68 | 5.38 | 8.9% |
| TMO | Thermo Fisher Scientific Inc. | $262.2B | 37.40 | 4.76 | 13.3% |
| DHR | Danaher Corporation | $166.6B | 38.78 | 3.07 | 8.2% |
| A | Agilent Technologies, Inc. | $51.1B | 35.66 | 6.95 | 20.5% |
| MTD | Mettler-Toledo International Inc. | $34.4B | 38.68 | 2,665.20 | -12.0% |
| WAT | Waters Corporation | $47.1B | 119.72 | 3.08 | 1.9% |
| CRL | Charles River Laboratories International, Inc. | $18.1B | 6.39 | -7.7% |
Price
| Price | $165.78 (closing price, October 29, 2026) |
| Market Cap | $18.5B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | 3.27% |
| Return on Invested Capital | 2.91% |
| Return on Assets | 1.97% |
| Gross Margin | 52.11% |
| Operating Margin | 12.32% |
| Net Margin | 8.16% |
Related companies: TECH · TMO · DHR · A · MTD · WAT · CRL · QGEN
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of RVTY: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks